MAP2K1 and non-small cell lung carcinoma: Six FDA‐approved and clinically available drugs were considered for the treatment of bTME+ and bTME‐ BM‐NSCLC cells, including afatinib (EGFR/ERBB2 inhibitor), PKI587 (PI3K/mTOR inhibitor), palbociclib (CDK4/6 inhibitor), Ceritinib (ALK inhibitor), dasatinib (Bcr‐Abl/Src inhibitor), and trametinib (MEK1/2 inhibitor).